Apeloa PharmaceuticalLtd Third Quarter 2024 Earnings: EPS: CN¥0.21 (vs CN¥0.21 in 3Q 2023)

Simply Wall St · 10/18 22:16

Apeloa PharmaceuticalLtd (SZSE:000739) Third Quarter 2024 Results

Key Financial Results

  • Revenue: CN¥2.86b (up 12% from 3Q 2023).
  • Net income: CN¥244.8m (down 2.2% from 3Q 2023).
  • Profit margin: 8.6% (down from 9.8% in 3Q 2023). The decrease in margin was driven by higher expenses.
  • EPS: CN¥0.21 (down from CN¥0.21 in 3Q 2023).
earnings-and-revenue-growth
SZSE:000739 Earnings and Revenue Growth October 18th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Apeloa PharmaceuticalLtd Earnings Insights

Looking ahead, revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China.

Performance of the Chinese Pharmaceuticals industry.

The company's shares are down 3.7% from a week ago.

Risk Analysis

It's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with Apeloa PharmaceuticalLtd, and understanding it should be part of your investment process.